TMDX - Earnings call transcript Q3 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, and welcome to TransMedics' Third Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. I'd now like to turn the call over to Brian Johnston from the Gilmartin Group.

Brian Johnston

operator. Thanks, released the TransMedics XX, ended results XXXX. financial today, quarter for September Earlier the available release website. copy press A of is on company's the

expectations events, Before pursuant and this in and in for like will would of the These federal statements we Private cause regulatory you which meaning safe this results begin, not management are approvals for Act implied harbor and forward-looking operating assumptions. examination laws, reliance that and/or margins upon anticipated risks guidance of or of potential Accordingly, made within organization, to performance the our without predictions make statements XXXX. call in the that Reform that by contained or including, call growth remind material or relate current during future various statements. securities include these Litigation to statements. on differ opportunity commercial products include undue those materially and should our forward-looking reimbursement Securities of you statements our of forward-looking I results for provisions and statements are based future expenses to or are statements. statements, the All actual estimates from involve our and revenue, expectations to could place Any operating forward-looking expectations XXXX gross these which trends, financial are limitation, that uncertainties events expectations,

is XX-Q by the information, disclaims now that, or uncertainties X, and to broadcast, with update and any call Risk our otherwise. events turn August of except the only any on quarterly on over or conference a of to projections to And time-sensitive description For TransMedics forward-looking Executive new risks President of with filed future Waleed I'll or as Securities obligation, XXXX. XXXX. business, live our Factors list Officer. today, statements, This financial November and with refer call required information or accurate please Hassanein, because intention Commission contains as the and whether Form law, associated Exchange revise the X, of the Chief section and report

Waleed Hassanein

Thank you, earnings quarter Brian. third to XXXX call. welcome everyone, TransMedics' afternoon, Good and

me is Gordon, Financial Joining Chief our Stephen today Officer.

of quarter TransMedics. third XXXX was The for transformative

OCS Our the OCS culminated Liver once positive System indicated Liver with the the we DCD broad the has was throughout been the supplement, clearance, System, as strategic one secured OCS line Heart year DCD language. OCS XXX(k) both labeling organ. DBD FDA of Namely, by indication DCD approval to momentum System PMA In for achievement trial. We two release look four forward and while in and with both with heart is September, top for to from The FDA Heart filed use of FDA our our approved as results expanding OCS well use positive catalysts. OCS include that Heart was approval, for organs, indicated DBD PMA FDA. premarket

decline results of Now, Net million QX third $X.X a $X.X for was the discuss for let QX. quarter me from million, financial XXXX. revenue the

As heart and QX anticipation both from not the renewed CAP revenues trials about adversely were we the and in revenue approvals. of trial by spoken previously, PMA were have impacted liver it expected that lack results for

QX. starting our variant QX forward beyond. products million, looking I'm We revenue, growth over impacting which transplant to Overall, $XX.X of year-to-date XX% negatively key XXXX Delta leveraging all represents the also was this lung the year in into in grow of revenue saw three and September resurgence to centers OCS XXXX.

across progress more let provide me our Now, detail initiatives. our on key

OCS to contrary has speculations, pre-approval approval, DBD some label the FDA indications. Heart heart very DBD the For broad

pool, to hours competitive has by thrilled the of market well as gives four the access cross-clamp This as transplant more. label. a current of heart heart us that the donor the approved our label or XX% time approximately DBD with position are large We unutilized

commercial validation negotiated Following post-market FDA quickly post-market process for Heart the FDA that activities. September. late commercial true that a to approval, with OCS new enabled in us activities we transition is This were to launched

As I've stated go-to-market have before, we three-pronged strategy. a

approval have in in OCS We half The OCS are centers additional expecting PMA of expanding year, our in year. catalyst We're OCS traction commercial expand will that were lead program next heart our early Heart growth pipeline the DCD OCS prioritizing see which the to activities. centers this expected XXXX. the recent will XXXX finally, OCS into and starting we're second product for of Then QX XXXX. in to tangible Heart in an Heart include involved in technology CAP clinical the we heart interest National should that expressed to growth be

turn let approval. Liver Now me into and DBD DCD the FDA

go-to-market market The FDA-approved from DCD We identical OCS and entire both liver for DBD access our which for are also donors. us heart label the with extremely the to pleased strategy is to Liver our gives transplant strategy. liver System,

centers growth add which early of also in expecting expanding prioritizing Liver are and to starting and a OCS expanding centers, liver QX We in our technology our into with momentum OCS Liver early Like should tangible early XXXX. National to commercial are are XXXX. XXXX, new Heart, we OCS see into we positive OCS traction lead OCS pipeline experiencing program to

in have expanded Northern OCS adding we National and OPOs our Diego's California the regional On nine presence QX. into regions, San program, OPO

goal XX We the are meet year-end. to track of before target regions on

we're important early the program. necessary have success the Liver we we're this of expanding XXXX. approved resources Heart long-term that now FDA, Meanwhile, Importantly, the by to and to program ensure build infrastructure three organs to OCS and National OCS continuing all in include

FDA is this continue throughout to Heart DCD XXXX. next The indication. initiative expect We OCS

U.S. or U.S. standard transplant clinical to Heart it Heart of clinical rate DBD considered use to The week, and preserve we high line Heart is best in latter or OCS the donor the in we criteria the outcomes last DCD the resulted trial. a exceeded met world. fairly bar XX% utilization the high assess outcomes. our DCD resuscitate, of As comparing by outcomes The randomized be announced very that post-transplant are top at results of to from and thrilled hearts

We and our have expect the supplement XXXX. of in week PMA approval Heart DCD filed already last PMA indication

broad of and the lung, unique and fully next a me Now, OCS forward to the year The thoughts indications. results, with are let plan XXXX. liver extracorporeal trajectory OCS our plan into FDA-approved to our remainder heart XXXX. to any to ability to for transplant reach summary States. and now leverage year a expectation finish lingering delivering system position We are of growth our The perfusion doubts United technology commercial heart execute highly signs we this on dispel the looking tangible is encouraging, for inflection XXXX in in tremendous and from this starting early across commercial the clinical for only and point about our liver

business technologies growth. are commercial heart on drive transplant our ability for to transplantation we any lung COVID extremely compared relying impact new We variants three is and will confident and negatively not our significant liver in OCS disproportionately TransMedics' technologies always and for growth commercial and heart to all business, are liver. now more indications. indication FDA-approved the resilient, only leveraging and with both lung that given Today,

to the contribution on million Finally, $X to OCS we initial our our to Gordon, refocus intend of to that, turn I to and in to Heart organization CFO, position the begin efforts Stephen financial the million, and revenue quarter a QX revenue year. the commercial next as Liver the will commercial see and in earnings provide full full-year expect call during be detailed range $X - to results guidance revenues. the from our we be We for XXXX call. the financial With review

Stephen Gordon

will on quarter the now financial other for detail additional provide I year. some third quarter results the Waleed. you, and and the information Thank

OCS all, three of approval of we longer clinical revenue now all no part will our received be First a sales. products, trial of our have that of

will be the net and on I same. gross no as So, are longer reporting they revenue both

by In the net revenue There in QX million, U.S., This third million drivers in by was from quarter. declined QX of performance million $X.X the $X.X net $X.X XXXX, lower were of two $X.X was for million quarter So revenue in from million. XXXX. of $X.X revenue of million declined which $X.X XXXX.

trial First, OCS COVID-XX $X.X pandemic. either [technical XXXX, revenue commercial no highly or OCS the of longer quarter difficulty] for for million trials Both by $X.X any Liver. revenue and for OCS programs and was OCS and that Heart the Lung. we had Access Protocol The Heart clinical U.S. a was million Continued related ex- impacted

due from for the to million. QX National preparing last our from Our sales gross margin from our quarter is main increased the up and for XX% drivers the $XX.X well to the of our which OCS it's expansion of growth of flat QX operating QX were compared for XXXX of and as XX% XXXX, resources to XXXX expenses This The were XX% third low product million. quarter and Program. unusually quarter at of was full of expenses XXXX, $XX.X total expense our line, was related as of COVID-XX for commercial

of the invest to as continued result infrastructure have the in we recent approvals. Secondarily, expected our growth a the FDA to business support in and overall resources

quarter the third XXXX compared Our third $X.X XXXX million of net million of quarter loss XXXX. was and $X.X quarter in of to in the $XX operating was third our $XX.X to of third quarter the the in loss million million compared XXXX for

Finally, for weighted balance million XXXX. $XXX.X end cash, And which quarter from cash reduction equivalents shares to securities the of of were were XXXX, equates a million as outstanding at the XX.X $X.X XX, million. September marketable and common of average QX the

expected and in XXXX. the full-year the Waleed ahead look for net representing X% 'XX. to to $X $XX.X million translates revenue generate we between This As to revenue million over of XX% quarter growth full-year and million million the we of fourth in mentioned, XXXX, and as $XX.X expect between $X

section comments. Now, call to to quite to Waleed asked as Yes, for I've closing reread back I revenue been it would clear. turn not the was like maybe the

U.S., that part. the was was just million sales $X.X million. and sales. Lung. I And So, are and I $X.X that's will revenue million net Outside $X.X net now the U.S., was OCS U.S. OCS commercial OCS was In Heart million in Lung Heart $X.X revenue million. that revenue OCS the was all reread of clear. hope net $X.X

Waleed Hassanein

has XXXX bumpiness transformative sales, year COVID proven Thank expected for Overall, to obstacles the you, and TransMedics. truly despite a be in Stephen.

will have to the for as achieved. be catalysts We XXXX that key well. an ambitious outlined every year, timeline in Earlier be major expectation we

and have every in year. in earlier that Here I'm we thrilled made we November, promise to we the are say delivered on

and expand clinical States. so executed National for And position as many growth higher to our even remain and our all the organ and three program, we technology, programs better our With families, on trajectory point. the transplants this have the throughout will and possibilities Operator? investigators market products in footing to In our OCS XXXX. teams the target across have and FDA-approved desperate turn broad the OCS to solid transplant on transform to growth extremely deliver TransMedics. labeling on embark we trial for path, leverage indications, who United patients, for steps answers. their our unique take to ever growth on OCS for questions than have commercial laser now we conclusion, unrivaled families with on to we focus our that, the donor XXXX, and for We We next plan goals helped transplantation. patients as are operator operational I call positioned technology organ With us grateful gotten

Operator

comes [Operator Plovanic Bill first Instructions] the from line Canaccord. from question of Your

Your open. line is

Bill Plovanic

end of couple have Wondering sites first kind color the a we just expect you for be Thanks. the program. questions of QX of metrics, what of full after into I'm then to the to of At could Just signed start some as And question do the for CAP OCS coverage? up, get kind where we and the sites QX? and National on at National at and the national both you and end the stood heart then you commercialization liver. you're trying of first, understand, study just Kind where second you're going OPOs you get if number program. of OCS is rolling additional my

Waleed Hassanein

Thank you, Bill.

had these transplant On of the followed the the national targeting centers, followed by program. pipeline by initial our go-to-market strategy components first well-defined three programs, question,

from the world been is we're for two liver we've commercial As demand, us now - three for seeing kind weeks, one and and the heart to two. with of, last several pulling to in

access to be and training that plan clear, the to clinical So we prioritize centers in to have OCS OCS. have

we're seeing the given initiated QX, the national pipeline dynamic pull programs However, The approval. to we expect thing post-FDA that may in applies their be there program. that - same

potentially earlier than national XXXX. pulled seeing even are We being program

that of perspective, so to to prioritize somewhere be to us to would centers XX I I trying trial two. program. - fully in granular that, anywhere active between in heart From commercially a say the will liver of we're suspect - seven QX, in the other active kind However, centers XX%, the XX% and similar puts we between

the centers in are We not the active QX. have full full to and centers liver XX going heart XX

in to that expect We happen XXXX. early

that's So first question. answering the

that of question, second don't going talk transplant involve not The national covering injected this to we are our program for on teams been Net-net, just hopefully, - to on lungs. national able that call. commercial OPOs nine obligated momentum that highlight I have the team's But is rely to heart and regions through active the the it the are the next also allocate some expand call, to are we want hopefully, be about to to we but to have organs, strategy into program. today program

our building across rapidly on a of are we program organs. full national that hoping three are question, XXXX, to the We QX Does infrastructure or QX, able answer that your breadth early livers be have here. we'll by And the Bill? very

Bill Plovanic

there, and about very and you having business there much. does, should – my liver. the think questions? yes how data you It if we this wondering taking just the impact could thank up the I follow just now I international is out an then for And that thanks heart have or for out approvals on was FDA if with

Waleed Hassanein

Thank you, Bill.

to I in see from business going tangible think, not but anytime that absolutely, international we're impact XXXX.

Just suspect our an we it in a do discussions impact having that, than markets of move major proof probably FDA and you of reimbursement see that. big XXXX. When can reimbursement half all organs that approved will of - formalized going some slower have they remains don't hurdle. by I to three is second assure Europe. with tangible help I earlier

Bill Plovanic

Great.

Waleed Hassanein

Just how nature that take because in of - things the long how things Europe.

Operator

of from the line Your JPMorgan. from comes Allen next question Gong

Your line is open.

Allen Gong

for and first liver kind first full you're So street is just the the like where to looking just it of portfolio. with coming be were providing target. in modestly second. given looks a both full this guidance know But below, the the I you're time diving year on quarter into at year, this a your will especially expectations that for heart added

it looks like if only sequentially. you're So about a I bit it, up think

how So, growth like platforms, little despite held sequential just I wonder well. be we if you the looks could right. provide in pretty should Delta, about a your three bit of in It guidance on thinking lung,

you flat? we So what liver, stay to fourth And into going then breakdown should expect or and in lung heart improve modestly the that is quarter, growth expect? between

Stephen Gordon

I can Hi, is Stephen. Allen, answer this question. that

conservative the have think I what been in to lung. So, because we're we of seeing Delta tend on variant,

there's there with some So, really - I much QX. to from still sequentially unknown COVID. in it's expect And lung don't QX growth out

some bad some lung weeks. good with transplants, have weeks we'll really have then but We

most was have of start will we a on I - we - early in as head a be approved the September. momentum bit because that think heart of

I will really So, stages most of there. liver, think be then at the just of the And we're commercializing. momentum early

will be that behind. So trailing

kind liver to So about give be of sense, it the same if that lead, and I that, kind of you would heart sense. expect, lung then makes to can a behind

Waleed Hassanein

But QX or Stephen significant of the at we expect and it overall, revenue at compared yes, was liver annualized to behind a zero. nearly build be to see what bit looking it some on lagging might liver But to where the zero QX, little QX, Allen, an just basis on sort said, heart.

to to So, of think that the just is three organs we Stephen the cadence giving pace, the revenue sort expect but Stephen see with I contributing the line described.

Allen Gong

able you I strong And while and then were they But trials. really from to their to historically, heart know just little be at clinical follow-up obviously were quick bit between going to different liver dynamics when generate the look undergoing are a we trial a volumes commercial.

same kind XXXX, reason about you once get of a half ramp-up first half move it's in think the centers to the per where Or cases think get period in more to kind back use you past do commercially? highlighted there the to ramp-up be you why shouldn't of we able Thanks you those, when prudent to we when of to Is gradual for kind back a any of stay expect guys. So that up around levels? unit of can bit a you expect and work lot, year? the they that center to conservative more as

Waleed Hassanein

Thank you, Allen.

I Allen lot least a reality. make same next to think level, if we see is above, And half expectation expectation that at second contributing - to think program the - not year of we at national above. hopefully, I of our be in the

So We're the that the demand the before. driver for here, With XXXX. a that, end innings here growth that see program beyond - we the what in just that's of program where - early are we be we've now. national awareness building stand right of even ever what at major potentially up we've as seen we before seen could forecasting

Operator

from the Morgan question next Cecilia comes from Stanley. of Your line Furlong

Your open. line is

Calvin Chu

Thanks for Cecilia. Calvin for questions. is the This on taking

from two me. Just questions

pretty DCD last line some top results week. positive announced You

change label 'XX? what's behind heart the here? next in acceleration to supplement the how I What So arm? adoption XX% pretty the So more XX% the little DCD OCS strong six-month data survival just a EXPAND from like versus, - DCD plus from path you? approval think, look the you commercialization about talk pooled think And does could rate looked I in and bit versus of think, of, I PMA was six-month here analysis CAP here EXPAND now submission the would with importantly, showing

Waleed Hassanein

Calvin. Yes. Yes. Thank you,

drive very, were data Meeting And in DCD strong, as happened. and our significant we've before. potentially see XXXX. very label adoption We But the domain. within We DBD, plan even goal Boston by DBD providing DCD additional really definitely, once the an the catalyst results here of stated we in continue to April end the in the heart to PMA transplant detailed see portion the that of being approved is So is held exposure to ISHLT publications the XXXX. expansion, here large time

we and punch see carrier approval, look we step the timeline of will a I catalyzing in footprint of All with happens. the will sort of to growth and Taking heart that our grow be once to be data. maximize two sort year awareness, expansion into DBD XXXX. the visibility indication. second a And, from one, that maximize as the later think both now until at a And label from back the of DCD hopefully, the will the effect DCD perspective, DCD approval that our the of a DBD a

Calvin Chu

my much event, just latest second can the bit curious, just question on kidney? what little - And talk any understanding, noting is but just progress about not on it's there. a XXXX is worth you a Very

you forward? going platform that guys. heart forward, driving of liver model sort how plan U.S. work with commencing launching Thanks on on the so and you do much, service As your focus kidney increasing those in start your and clinical balance to

Waleed Hassanein

part indications. not laser potential. the not I'm to it in distraction. partially in team But is of commercial the concern commercial and top of our or at That said, a Thank only priority an dedicated that's question, kidney distraction, To about kidney in important in to heavily avoid within next are our all three from you, organization our Calvin. our involved focus sort call. programs have to is address any approved question, address strategy being will that growth Great growth I and plan going fully that a pursuing we that our involved address long-term Calvin.

liver XXXX, setting a here. of start getting - should stop end and And to head That in see to XX we solidified of heart, in potential lung will strategy give I map the States. of, kidney program. months out kind year our enough that to us start kidney on first call as the plan commercial United So, as we in the next

Operator

comes and from of next from Your question Jennings Josh the line Cowen Co.

line Your open. is

Brian Kennedy

I referenced heart Brian This questions. the your To assumptions about second for timing start, you the I expected remarks. believe XXXX DCD you prepared an approval here is taking Josh. behind approval? in my half can in ask Thank the of for

timing by And six review assumption? this of and if so? have the I are follow-up, I you can. of factoring does a filing year-end months possibility assume panel a So generally in your a a And or in

Waleed Hassanein

filed. Brian. PMA Yes, the been supplement already Thanks, has

So, assuming if going or whether have of been give time we to panel. filing. It's to filed. the review team XX-months horizon. we're do, give we're ample a already we And feedback to not us to not But sort concrete have assume we

panel for Brian, possibility ability case. that. that's review. baked into timeline all going confident very FDA our in if assume buffer from a the feel is has we that to the giving we perspective, we go for and the that when secure predict positive are indication. a about that, be very to to ensure through have to we to data. feel full timelines never to PMAs But If prepared a flexibility, don't have But So, we indication another that we and we're panel, we under comments know that have confident But our

the So are comments intended achieve. what that's to

Brian Kennedy

would be referenced I investors. to think DBD on your about the label just was think the gave when third but DBD month. believe tracked - whether quarter, well? on how Heart, you a this less some confusion in label. this, experiencing on was you you specifically you also in than the Can broadness technical in sales difficulties I in comment there this field I just of But comment a the And you about can confusion referenced reference $XXX,XXX I among the Heart expectations? noise was which U.S. for some relative And as to

Waleed Hassanein

Brian. you thank Sure,

meeting. the investors the that the actual as discussions did from and some the heart specific with bottom remarks comments donor the pool of not they're access we very line of it after the themselves pool - about was outlined I us our and really indication came we for DBD made speaks The large, We noise to any prepared unutilized in the heart is issues panel - community. gives with sort of the transplant pool. pre-approval broad. experience speculation Street that And donor huge So,

In gives hours access heart right addition, XX% cross-transplant. the it of existing cases transplant us are more four approximately to that of or away of

very So, that is important.

on kind the panel investors were So concerns remarks of and the specifically the Street that came out meeting. after

$XXX,XXX Regarding spend time listen the lot weeks, revenue or on path. two a we of we in half stated new two always working and whole that mapping of FDA a weeks with out

look commercial post-market not For pre-commercial do to I is conversion the for working. process the validation anywhere and to did trials accelerate - accelerate to what think had actually that from adoption solid revenue to from pace lung to close we've commercial. is this the And conversion that $XXX,XXX the a

achieved hoping we that, were it. achieve and we so, to And

hope it to a to we the So with for able negotiated FDA. be us, achieve wasn't process was It surprise. always the with that

hope we're in XXXX. and that looking continuing addresses monitoring your pace into forward Brian. So, QX I to question, that

Operator

Instructions] Kalia from the Oppenheimer. [Operator comes of Suraj next question line from Your

Your line is open.

Suraj Kalia

you utilization you terms think data QX and do DCD really to now in map on out to all if center next quarters? were and to increasing you the would the on as of you eight to necessary feet organ more versus basis, what looked program OCS quarters National as So four increase overall utilization do good. mentioned, an beyond, look Waleed, How think be versus Heart the all per publications ground I over you with just think the chart pie a

Waleed Hassanein

has several the the in leadership the heart reminding weeks, community multiple the factors very important and national That's community results. Suraj, and webinars commercial Thank the engaged for utilization results. drive Suraj. of team three the One three adoption. awareness Right to liver entire we one-on-one our on key now, important and - key focusing critical. see a trial deeper of is question. is been heavily you, important here of last It

we market. the starting the results, get So it execute goal in to DCD what prong to so aggregated them highlight of that the much, in not is and using don't engaged the too with the technology the them and haven't highlight time. it near-term - one community used then and and which the is with they DBD means, EXPAND confuse And a next the you engage reacquaint Hearts, long results number results but

So hands the engaged getting is data that their program. the what results and that now own rolling. saw gold. these element the now that its the - generates momentum from starts hands weight and then national third own into in their in ball is replicating worth then and theoretically the data translated That's they ball And the

think COVID, any lived can are They're them of solution. in evaluating deliver is the do us, engaging these at the we're community turnkey transplant procure the organs hopefully, is see with and be to dealing nobody further going I a the right Suraj, and the the we've lung mindsets feedback the brunt now, colleagues what us, national are us in it's to and for through early they majority it if to And changing. that truly we really once they're the nights really hearts out doing catalyst a longer. cases program, in the - initiated that middle of looking hearing - they huge go of want or lung. partnering livers with on on positive now And driver with, not for adoption. Because

to high-impact journal be ISHLT And outcome fulsome will that community two a a on track get your more that. data published to of the But are a here meet fully for is growth of full been last going throughout last trial continued Meeting sure hopefully, in for by about everything is are the putting we for talking the the DCD forums year. a element are well the to hope The program in two-year six or the targeting. That all addresses as that that targeting. last see as EXPAND one make the published for the question, open months on we data this ISHLT. that throughout that scientific and top the We're national we results going that, the I dispersed catalysts an data, nine highlighting we're to we've we papers, So, program XXXX, on to the published, into do deliver months target onus ourselves the Suraj. data deeper Meeting. for ISHLT like year-end. Boston before one all is be for form case heart as And to in planned

Suraj Kalia

- And could, I'll It's sub-part my for queue. back question. in the Waleed, a for question, and if I hop second

have seen you're field good. OCS to single And getting need is harmonizing is also, for the a Thank you pockets the you And right? specifically exceptionally for we heart worldwide? there Waleed, for do the the feel my in questions. What taking pushback any data, indication? is data protocols So in related for most more

Waleed Hassanein

questions Very always. Suraj. Thank you, as important

the reimbursement with she how joined just The is first seeing today, about hurdle potentially reimbursement really the one, in new the have biggest not optimize today And that Abbott kind That these to And even And to from for to October, the the flow. jitters make is understanding how of to reimbursement, early Black they dollars. tremendously structure programs and accommodate the reimbursement only is the understand ex-Thoratec, money we national the lack a leader. early optimizing just November cost. optimize pushback and reimbursement, we're service and of to known commercial concerns program we well dollars. Belt expert is the team wanting that of heart OCS buttressed address failure our field us sure but late and get liver heart reimbursement helping

the harmonization, you bringing for this the of thank part On question, up. second the

that to in discussions we start starting We have FDA going we leading now academic in and it the program. the ACT are engaged societies We're Meeting the national June path expanding with scientific of actively because have at April, ISHLT at approval, society in the CMS.

all that in we Now, we're now reengaging, approvals have hand.

these which care, XXXX for involved key will that be we in catalyst heavily and standard goal have driver next and to initiatives see going towards the protocols of and a really for and lot of the OCS activities a So, changes. of redefining harmonization we will are

Operator

at this any see closing don't remarks. over it I back turn any for time. I Waleed will question to

Waleed Hassanein

all very you, Thank join We tonight. thank time for taking the you much us operator. to

of call. a our you and next speak the we'll much. very great forward And looking soon. are Thank end have year We to

Operator

today's conference This concludes for call. participating. Thank you

now may You disconnect.

TransMedics (TMDX) 10 Nov 212021 Q3 Earnings call transcript